Photodynamic therapy (PDT) is a relatively new modality for anticancer treatment and although the interest has increased greatly in the recent years, it is still far from clinical routine. As PDT consists of administering a nontoxic photosensitizing chemical and subsequently illuminating the tumor with visible light, the treatment is not subject to dose-limiting toxicity, which is the case for established anticancer treatments like radiation therapy or chemotherapy. This makes PDT an attractive adjuvant therapy in a combined modality treatment regimen, as PDT provides an antitumor immune response through its ability to elicit the release of damage-associated molecular patterns and tumor antigens, thus providing an increased antitumor efficacy, potentially without increasing the risk of treatment-related toxicity. There is great interest in the elicited immune response after PDT and the potential of combining PDT with other forms of treatment to provide potent antitumor vaccines. This review summarizes recent studies investigating PDT as part of combined modality treatment, hopefully providing an accessible overview of the current knowledge that may act as a basis for new ideas or systematic evaluations of already promising results.
Photodynamic Therapy
In recent years, there has been increasing interest in the potential of using photodynamic therapy (PDT) to treat various types of cancers, either on its own or in combination with other anticancer treatments. The principle of PDT includes the administration of a photosensitizing drug and subsequently illuminating the target area with visible light corresponding to the absorbance wavelength of the photosensitizing drug, triggering a series of biological effects. 1, 2 Thus, there are 2 main components that govern the applicability of PDT in cancer therapy, the localization of the photosensitizing drug in tumor tissue and delivering the appropriate dose of light (near-infrared for most photosensitizing drugs) to that tissue. The characteristics of an ideal photosensitizing drug have been extensively described elsewhere, [3] [4] [5] but a few key features include high-specific tumor uptake, negligible dark toxicity (biological effects without light application), and a fairly long absorption wavelength as longer wavelengths allow deeper tissue penetration. Some of the most investigated photosensitizing drugs include hypericin, [6] [7] [8] Photofrin, 4, 9 and 5-aminolevulinic acid. 4, 10 Alongside a wide variety of photosensitizing drugs, there is a vast availability of light sources for PDT such as various types of lasers, broad wavelength band lamps, and light-emitting diodes. 9, 11 Figure 1 illustrates the photophysical and photochemical mechanisms that lead to the biological effects of PDT.
Immunogenic Cell Death and PDT
Considerable research efforts have been undertaken to clarify the biological mechanisms responsible for the anticancer effectiveness of PDT. These mechanisms can generally be divided into direct antitumor effects and indirect effects related to an induced immunological response. The cell death mechanisms of direct PDT-induced cytotoxicity include apoptosis (programmed cell death), necrosis (unregulated cellular breakdown), and macroautophagy (degradation of cellular components by lysosomes). 2, 7, 12 Direct effects can also include damage to tumor vasculature, which may however initiate subsequent tumor angiogenesis. 7, 12, 13 Which cell death mechanism is responsible for the antitumor effects depends on the light dose and photosensitizer (PS) uptake. The amount of apoptotic versus necrotic cell death depends on the resulting reactive oxygen species (ROS) concentration within the cells after PDT. 7 Photodynamic therapy has been shown to induce immunogenic cell death (ICD) that can trigger a considerable immune response further enhancing the antitumor effect. 14 A detailed review on ICD was recently published by Kroemer et al 15 where the authors provide the following operational definitions of ICD:
Malignant cells are considered to undergo ICD in vitro if upon subsequent transplantation they provide the host with an immune response that protects against challenges with tumor cells of the same strain, that is, acting as a cancer vaccine. In vivo, cell death is defined as immunogenic if it triggers a response of the innate and adaptive immune system leading to antitumor effects that are a result of mechanisms dependent on the immune system. Figure 1 . A ground state photosensitizer (PS) molecule in singlet state is excited by light boosting an electron into a higher energy orbital. The excited state reverts to the ground state via fluorescence or internal conversion (nanoseconds) or the spin of the excited electron inverts resulting in an excited triplet state PS at lower energy, which is a relatively long-lived state (microseconds) since the excitation energy is lost by phosphorescence in a spin-forbidden transfer directly back to the ground singlet state. The excited triplet state can then either transfer its energy to triplet molecular oxygen resulting in biologically reactive excited singlet state oxygen or transfer an electron to superoxide anions resulting in various reactive oxygen species (ROS) capable of causing substantial biological damage. The resulting biological effects of photodynamic therapy include cell death through different pathways and in many cases also a potent immune response involving both the innate and the adaptive immune system.
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The innate immune response includes activation of the complement system with a strong inflammatory response and neutrophil infiltration, along with macrophage activation, maturation of dendritic cells (DCs), and increased natural killer cell activity. 14, 16 Adaptive immunity is mediated via B-and T cells. B cells produce antibodies that can in turn eliminate tumor cells. T-helper (T h ) cells can both induce and suppress immune effects. On one hand, T h 1 cells (CD4þT-betþ T-cells) activate and stimulate antitumor M1 macrophages as well as license CD8þ T-cells to become cytotoxic T-lymphocytes (CTLs) that kill cancer cells. While on the other hand T h 2 cells (CD4þGATA-3þ T-cells) stimulate B cells into proliferation, induce B-cell antibody class switching as well as activate and stimulate protumor M2 macrophages. Additionally, regulatory T cells (T regs ; CD4þCD25þFoxP3þ T-cells) suppress the antitumor immune response through induction of anergy in T h 1 cells and CTLs. 12, 14 Immunogenic cell death is triggered by the release of damage-associated molecular patterns (DAMPs), which are normally retained within the cell but act as danger signals in response to damage or stress by being translocated to the cell surface, secreted into the cytoplasm, or released extracellularly. 16, 17 The release of DAMPs prompts an efficient donation of tumor antigens priming the adaptive immune system to create antibodies and seek out the corresponding cancer cells. Damage-associated molecular patterns include calreticulin, heat shock proteins (HSPs) 70 and HSP90, high-mobility group box 1 (HMGB1), adenosine triphosphate (ATP), uric acid, interlukin 1a, DNA, and RNA. 16 Thus, it has been shown that a robust approach to determine whether cancer cells subjected to a certain treatment undergo ICD is to measure subsequent calreticulin exposure, ATP secretion, and HMGB1 release. 15 It has been shown that 2 essential components required to trigger the intracellular mechanisms resulting in ICD are endoplasmic reticulum (ER) stress and the generation of ROS. 18 This is explained in further detail in the review by Krysko et al, 18 but it has been extensively shown that both ER stress and ROS are required to elicit ICD. Interestingly, the strongest immune response is provided by treatments inducing focused primary ER stress rather than ER stress induced as a secondary effect through damage to other intracellular targets. This makes PDT an important candidate for ICDbased cancer therapy as hypericin-PDT has been shown to induce massive ROS production generating direct ER stress, as hypericin localizes within the ER. 19, 20 This suggests that the immune response resulting from hypericin-PDT will be more efficient than immune responses from treatments inducing secondary ER stress, as focused ROS-based ER stress has been shown to result in an increased number of emitted DAMPs as well as simplifying the DAMP trafficking pathways. 18 In the following sections, we summarize the current preclinical, and in a few cases also clinical, evidence of the efficacy of PDT when used as part of combined modality anticancer treatment.
Photodynamic Therapy in Combination With Immunostimulants
Since PDT has the potential of triggering a strong antitumor immune response, there has been great interest in potentiating this effect by stimulating various components of the immune system. 21 This can be done by combining PDT with the administration of various immunostimulants to, for example, increase neutrophil infiltration, enhance tumor antigen presentation, upregulate T-cell activation, and suppress expression of T regs . Immunostimulants can be administered intratumorally, intravenously, or even topically depending on the type of malignancy. 21 Table 1 summarizes recent studies exploring different immunostimulatory agents and their effect on immune response when combined with PDT for various malignancies.
Studies have been carried out on several different tumor models including lung cancer, colon cancer, squamous cell carcinomas, melanoma, and breast cancer. Many of the different strategies showed promising in vivo results with increased survival and reduction in tumor volumes. There were also some clear immunotherapeutic effects of these combination strategies showing effective rejection of tumor rechallenge or significant antitumoral effects of untreated contralateral tumors. Many of the studies used Photofrin as the PS agent, although some studies showed that the increase in therapeutic effect from combination therapy was independent of the choice of PS. 26, 27 As different studies addressed different mechanisms for enhancing tumor immunogenicity, there may also be potential for combining some of the strategies to further improve treatment results. This should of course be done with caution and considerable thought has to be given to how immunostimulants are administered, as systemic effects could result in severe autoimmune reactions.
Photodynamic Therapy in Combination With Established Anticancer Therapy
The combination of PDT and established anticancer therapies such as ionizing radiation and/or chemotherapy provides an exciting platform for potential new treatment options, especially since PDT does not have the inherent dose-limiting toxicity of either radiation therapy or chemotherapy.
The combination with ionizing radiation also includes the potential of certain PS agents to act as radiosensitizers. 33 Since ionizing radiation causes cell death mainly via direct DNA damage, there are potential synergistic effects to be explored as PDT can cause DNA degradation leading to increased cell death as the DNA may lose its capacity to repair normally sublethal single-strand breaks. 34 When it comes to combining chemotherapy with PDT, there are many possible ways of achieving a combined or synergistic effect, depending on the cell death mechanisms of the chemotherapeutic drug in question. Not only are the cell death mechanisms important but also the intracellular target of the chemotherapy agent, as this will likely affect how the combination with PDT affects the tumor cells. As PDT also affects the cell membrane permeability, adding it as an adjuvant to chemotherapy may increase the deliverability of cytotoxic drugs. Some chemotherapy drugs can act both as a cytotoxic agent and as a PS, providing the option to illuminate the tumor tissue after chemotherapy administration in order to elicit a potentially synergistic treatment effect. 35 The interest in this combination therapy does not only lie in enhancing the antitumor effects but also in the ability to reduce the risk of severe side effects by reducing the required chemotherapy dose. 36 Tables 2 and 3 summarize the experiments and results of several recent studies combining PDT with either chemotherapy or ionizing radiation. Most of the studies combining ionizing radiation with PDT showed an additive antitumor effect of the 2 treatments, when either a cobalt-60 ( 60 Co) or cesium-137 ( 137 Cs) source was used. There was, however, a potent increase in cytotoxicity shown in 1 study of human MCF-7 breast cancer cells receiving PDT and treatment with 100 kV x-rays. 35 Interestingly, the studies investigating the order in which PDT and ionizing radiation were administered found that the effect of combination therapy was independent on which treatment preceded the other. 33, 37, 38 As for the combination with chemotherapy, many alternatives have been explored and one quite interesting finding was the highly increased treatment efficacy of drug-resistant murine leukemia and human uterine sarcoma cell lines, when PDT was added. 36, 46 In these cases, PDT might prove a promising addition or even alternative to chemotherapy. It was also shown that PDT in combination with cisplatin resulted in a considerably increased in vitro and in vivo antitumor effect, which may prove very useful considering the often dose-limiting toxicity of cisplatin. 40, 41 One study also examined the combination of PDT, chemotherapy, and adoptive immunotherapy with splenic lymphocytes, adding a further dimension to the combination approach. 47 This triple combination proved effective in treating an aggressive murine leukemia model in vivo, where either PDT alone or chemotherapy alone was ineffective. Although very promising, great care should be taken when attempting to translate this into a clinical alternative as the addition of each new treatment regimen potentially increases the risk of severe, and possibly systemic, treatment-related toxicity.
Photodynamic Therapy in Combination With Experimental Anticancer Therapy
There are several anticancer treatment strategies that are currently not well established in the clinic, used on an experimental basis, or are still being tested in the laboratory. Two such strategies are hyperthermia and focused ultrasound (sometimes referred to as sonodynamic therapy).
In relation to PDT, hyperthermia can cause damage to the tumor vasculature that would affect angiogenesis and, just like PDT, damage the cell membranes, which could allow for a synergistic effect between the 2 treatments. 48 As the use of focused ultrasound in the management of cancer is fairly new, the combination between PDT and ultrasound has only started to be explored in the last few years. The main hypothesis suggesting that this combination may yield a considerable antitumor effect is based on the fact that there are PS agents that can be triggered by both light energy and ultrasound energy, which should potentiate the response. 49 Tables 4 and 5 summarize the results of studies performed to evaluate the potential antitumor efficacy of PDT in combination with either hyperthermia or focused ultrasound. Photodynamic therapy in combination with hyperthermia has been shown to yield a strong direct cytotoxic response but also to prompt a considerable antitumor immune response. 13, 50 Some studies have shown that the timing between therapies is of critical importance and that hyperthermia applied after PDT is more effective than the reversed order. 13, 48 There also appears to be a considerable dose-response effect dependent both on the light dose and on the length and temperature of hyperthermia, 53, 54 suggesting that there is a need for systematically evaluating this dose-response relationship, in vitro and in vivo, to obtain the optimal treatment parameters for different cancer types.
Although very few studies have been conducted so far, the experience of PDT combined with focused ultrasound suggests that this combination can provide a strong and synergistic antitumor response. Interestingly, some studies found that the response was most pronounced when ultrasound preceded PDT, and it has been suggested that this is caused by increased ROS generation due to enhanced PS uptake as a result of ultrasound-induced increase in cell membrane permeability through sonoporation. 49, 55 This also suggests that a combination of focused ultrasound, PDT, and chemotherapy may be promising as both PS and chemotherapy drug uptake can be enhanced.
Combination Therapy and Tumor Hypoxia
Tumor hypoxia presents a major challenge in cancer therapy, and hypoxic tumors are often much harder to treat than welloxygenated tumors, something that is a common problem in, for example, radiation therapy of head and neck tumors. In PDT, hypoxia is clearly a substantial problem as the lack of oxygen in the tumor cells leads to significantly less ROS generation. To achieve an efficient tumor response under hypoxic conditions, combination therapy would have to be optimized to promote some form of tumor reoxygenation. It is often the center of the tumor that is the most hypoxic, and in this case, one option could be to apply fractionated radiation therapy to effectively treat the oxygenated outer parts of the tumor. This would eventually lead to some reoxygenation of previously hypoxic tumor cells that are still viable, and at this point radiation therapy could be combined with PDT to effectively treat the previously hypoxic parts of the tumor. Another option would be to combine PDT with hyperthermia, which has been shown to target tumor vasculature, which can subsequently initiate tumor angiogenesis, leading to reoxygenation of tumor tissue. 12, 13 Such an approach should, however, be explored with caution since increased tumor angiogenesis can lead to an increase in tumor growth. All in all, the effects of a hypoxic tumor environment will impact the effectiveness of combination therapy involving PDT and should be considered when evaluating different treatment options.
Summary and Conclusions
A considerable amount of preclinical evidence has been gathered regarding the combination of PDT and other forms of anticancer treatment, and this seems to be increasing rapidly. In this review, we have shown that the potential of using PDT as part of combination therapy is being investigated from many different directions, with promising results in terms of direct cytotoxicity as well as prompting a strong antitumor immune response.
A promising option that has been explored is the addition of low-dose cyclophosphamide (CY) prior to PDT in order to deplete the number of T regs . 29 This combination has led to a strong antitumor response, and more importantly tumor rechallenges were only resisted in mice receiving a second CY administration at the time of rechallenge. This shows the importance of T reg depletion and the potential of combining this not only with PDT but possibly with other anticancer treatments as well. Another promising option is anticancer vaccination using immature DCs that have been treated with PDT. 31, 32 This DC priming elicited substantial immune responses, and there was even a clear growth inhibition of C26 tumors in naive mice that received splenocytes from mice treated with PDT and immature DC injections.
Adding a further dimension to this approach, Canti et al tested the combination of PDT and chemotherapy, plus adoptive immunotherapy with splenic lymphocytes from PDTtreated mice. 47 This resulted in successful treatment of an aggressive metastatic murine leukemia model, a quite promising result, especially considering the many potential extensions or alterations in this therapy combination, including also other treatment modalities. Yet a further interesting result was obtained when combining PDT with 60 Co ionizing radiation for various nonsmall cell lung cancer (NSCLC) lines. 38 Using this combination of therapeutic agents, a less synergistic effect on normal lung fibroblasts compared to the NSCLC cells was found, suggesting a potential increase in the therapeutic window using this approach. Yanase et al used hyperthermia in combination with PDT in order to more effectively treat deep-seated tumors. 51 Their results showed promising antitumor effects from combination therapy, where neither PDT nor hyperthermia alone was an effective treatment. The inefficiency of treating deep-seated tumors is an inherent difficulty in PDT as most of the PS absorbance wavelengths do not penetrate far into tissue. Thus combination with hyperthermia seems to be one promising alternative, although combinations with ionizing radiation or chemotherapy could also provide a way to circumvent this problem.
The use of focused ultrasound to increase cell membrane permeability seems to be an effective method to increase intratumoral ROS generation and substantially enhance the antitumor efficacy of PDT. 49, 55 This approach holds great potential as neither PDT nor ultrasound is inherently dose-limiting treatments, so applying this combination also as an adjuvant to chemo-or radiation therapy may be a very interesting option.
Future Perspectives
With the availability of many different photosensitizing drugs and the large number of possible treatment combinations, there is a need for systematically evaluating the optimal doseresponse combinations and making sure the risks of increasing treatment-related toxicities are low. This need for systematic evaluation is further highlighted by the heterogeneity in PDT parameters among the studies included in this review. Taking the in vivo experiments as an example, the drug concentrations ranged from 0.1 to 250 mg/kg and light doses from 50 to 360 J/cm 2 , with large variation even between studies using the same PS. The ideal PDT setting in a combination therapy approach will therefore have to be assessed by systematically investigating different photosensitizing agents, concentrations, and light doses to find the optimal parameters for a certain indication. This will require a great deal of work, and the results will likely not be directly transferable between different tumor types.
The ideal combination therapy involving PDT will be one that can reach deep-seated tumors, show synergistic cytotoxic efficacy, promote a strong antitumor immune response, enhance tumor-specific drug uptake, and reoxygenate hypoxic tumor tissue. Based on this review, it is not straightforward to conclude which of the combination approaches comes closest to the ideal situation, but it will likely require the combination of several different treatment modalities.
Despite the fact that many of the suggested strategies may never reach clinical applicability, and the ideal combination therapy has yet to be found, PDT as part of combination anticancer treatment shows great potential and promise based on the current preclinical evidence.
